Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

The market for drugs that encourage the immune system to attack tumors could explode in the next three years, leading Bristol ...

By Ludwig Burger and Michael Erman (Reuters) -Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

This acquisition significantly built upon Pfizer's capabilities in antibody ... global licensing agreement (excluding China) with 3SBio, Inc. for SSGJ-707, an investigational bispecific antibody ...

CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...